anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (??) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of ?? and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (??) peptide and an alpha-synuclein peptide.
The present invention discloses a kind of Chinese medicine composition treating diabetes and preparation method, uses Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Cortex Lycii, Rhizoma Smilacis Chinensis, Semen Coicis, Haematite grass roots, Pancreas Sus domestica and the former dew of EM etc. to be prepared from.Pancreas Sus domestica is the essence of flesh and blood, is the thing in sweet cold sliding pool, and sweet cold then body fluid is raw, and sliding pool is the most dirty greasy to be gone.The insulin that Pancreas Sus domestica extracts can reduce blood glucose.Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. clearing heat, detoxicating, dispelling dampness is subsided a swelling, and has antipyretic and hepatoprotective effect.Cortex Lycii clearind deficient heat purging fire and cooling blood, can help releasing of quenching one's thirst and cough, Rhizoma Smilacis Chinensis and Semen Coicis expelling wind and removing dampness spleen invigorating, relieving cough and resolving phlegm, is suitable for the evil poison eliminating diabetes, Haematite grass roots removing dampness and detoxicating, being good at treating diabetes, all medicine compatibilities treat diabetes from source of disease strengthening vital QI to eliminate pathogenic factors, satisfactory for result.For treating the medicine of diabetes, assembling scientific and reasonable, determined curative effect, easy to use, from old complaint, physically and the most multi-faceted treatment diabetes, good and cheap, curative effect is excellent.
Background Sublobar resection for lung cancer is usually guided by cutoff values for consolidation size (maximal diameter of the solid tumor component) and consolidation-to-tumor ratio (CTR). The effects of these factors as continuous variables and the reason for established cutoffs are, to the knowledge of the authors, unexplored. Purpose To quantitatively assess the predictive value of CTR and consolidation size for cancer recurrence risk after sublobar resection in clinical stage IA lung adenocarcinoma. Materials and Methods This retrospective study reviewed sublobar resection for clinical stage IA lung adenocarcinoma performed between January 2010 and December 2019. A restricted cubic spline function verified linearity by estimating recurrence probabilities using CTR and consolidation size obtained on preoperative CT scans. Statistical analyses included a Cox proportional hazards model to identify risk factors for cancer recurrence and the Cochran-Armitage trend test for the association between CTR and consolidation size. Results Of 1032 enrolled patients (age, 63.9 years ± 9.9 [SD]; 464 male patients), 523 (50.7%) and 509 (49.3%) underwent wedge resection and segmentectomy, respectively. Among patients with a CTR between 1% and 50% (n = 201), 187 (93.0%) had a consolidation size of less than or equal to 10 mm (P < .001). There was a positive association between the risk of recurrence with CTR and consolidation size (r2 = 0.727; P < .001). The recurrence rate showed the greatest increase when CTR was greater than 50% or consolidation size was greater than 10 mm. Specifically, the recurrence rate increased from 2.1% (three of 146) at 26%-50% CTR to 8.3% (nine of 108) at 51%-75% CTR, and from 4.4% (eight of 183) for 6-10-mm consolidation size to 11.9% (23 of 194) for 11-15-mm consolidation size. The probability of recurrence exhibited linearity and increased with CTR and consolidation size. Conclusion Cancer recurrence risk after sublobar resection for stage IA adenocarcinoma consistently rises with CTR and consolidation size. Current guideline cutoffs for sublobar resection remain clinically relevant given observed recurrence rates. © RSNA, 2024 Supplemental material is available for this article.
During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
The invention discloses a Chinese medicinal composition, a medicinal preparation and a preparation method thereof. The Chinese medicinal composition comprises the following active ingredients in part by weight: 10 to 30 parts of gecko, 10 to 30 parts of cordyceps sinensis and 10 to 30 parts of deer penis. The Chinese medicinal composition can be applied to preparation of the medicinal preparation for treating asthma, pollinosis or dysmenorrhea. The medicinal preparation contains the Chinese medicinal composition provided by the embodiment and pharmaceutically acceptable auxiliary materials. The preparation method of the medicinal preparation comprises the following steps of: 1) respectively grinding the dried gecko, cordyceps sinensis and deer penis into fine gecko powder, fine cordyceps sinensis powder and fine deer penis powder; 2) mixing the fine gecko powder, the fine cordyceps sinensis powder and the fine deer penis powder in a weight ratio of (1-3): (1-3): 1 to obtain mixed medicinal powder; and 3) preparing the mixed medicinal powder into the medicinal preparation. The medicinal preparation can be honeyed pills, granules, tablets, capsules, powder or oral liquid.
An oral pouch product includes an outer wrapper defining a cavity and an inner filling material in the cavity. The outer wrapper includes a hydrophobic material or an elastomeric material. The inner filling material includes a dry mixture and a liquid mixture. The dry mixture includes a cellulosic material. The liquid mixture includes a triglyceride and liquid nicotine dissolved in the triglyceride. The triglyceride is included in the oral pouch product in an amount of 10% to 30% by weight based on the weight of the oral pouch product.
Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
Hyaluronic acid is a glycosaminoglycan formed by glucuronic acid and N acetylglucosamine disaccharide units. It is found mainly in the extracellular matrix of the loose connective tissue and is associated with several key processes, including cell signaling and repair, as well as with tissue generation, morphogenesis, and structural organization of the extracellular matrix itself. In clinical terms, its role is well known in conditions such as mouth ulcers, where its barrier effect relieves symptoms. Chondroitin sulfate forms part of the glycosaminoglycan group in the extracellular matrix, which is in turn formed by D-glucuronic acid and N-acetylgalactosamine. It has been shown to protect the epithelium of the esophageal mucosa by shielding the epithelial areas damaged by acid, thus diminishing catabolic activity and inhibiting proteolytic enzymes (e.g., metalloproteases, collagenase, or elastase). Chondroitin sulfate also regulates several inflammatory mediators (TNF-α, IL-1β, COX-2, PGE2, and NFκB) and reduces the synthesis of nitric oxide, which is involved in the inflammatory cascade. Polaxamer 407 is a bioadhesive component that acquires the active ingredients of ZIVEREL® adhere to the damaged mucosa and are not dragged away by the ingestion of food and liquids.
MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
Three high intensity interval exercise sessions per week of 40 minutes duration per session. Exercise will be performed on ergometerbikes.
A medical alert system for actively monitoring biological parameters of a user includes a computer system and an electronics module. The computer system is coupled to a computer network. The electronics module is coupled to a band that is configured to couple around a wrist of a user. The electronics module comprises a plurality of first sensors and a transceiver. Each first sensor is configured to assess a respective biological parameter of the user. The electronics module is configured to selectively and wirelessly communicate the respective biological parameter to the computer system and a primary care physician of the user, positioning an operator of the computer system and the primary care physician to selectively contact emergency personnel to assist the user.
PREMISE: Cytogenetic traits such as an organism's chromosome number and genome size are taxonomically critical as they are instrumental in defining angiosperm diversity. Variations in these traits can be traced to evolutionary processes such as polyploidization, although geographic variations across cytogenetic traits remain underexplored. In the pantropical monocot family Zingiberaceae (~1500 species), cytogenetic traits have been well documented; however, the role of these traits in shaping taxonomic diversity and biogeographic patterns of gingers is not known.
METHODS: A time-calibrated Bayesian phylogenetic tree was constructed for 290 taxa covering three of the four subfamilies in Zingiberaceae. We tested models of chromosome number and genome size evolution within the family and whether lineage age, taxonomic diversity, and distributional range explain the variations in the cytogenetic traits. Tests were carried out at two taxonomic ranks: within Zingiberaceae and within genus Hedychium using correlations, generalized linear models and phylogenetic least square models.
RESULTS: The most frequent changes in chromosome number within Zingiberaceae were noted to be demi-polyploidization and polyploidization (~57% of the time), followed by ascending dysploidy (~27%). The subfamily Zingiberoideae showed descending dysploidy at its base, while Alpinioideae showed polyploidization at its internal nodes. Although chromosome counts and genome sizes did not corroborate with each other, suggesting that they are not equivalent; higher chromosome number variations and higher genome size variations were associated with higher taxonomic diversity and wider biogeographic distribution.
CONCLUSIONS: Within Zingiberaceae, multiple incidences of polyploidization were discovered, and cytogenetic events appear to have reduced the genome sizes and increased taxonomic diversity, distributional ranges and invasiveness.
Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
A pharmaceutical preparation for the treatment of vascular, particularly cardiovascular, diseases comprises an oil extracted from the seeds of Oenothera biennis L. (evening primrose), g -linolenic acid itself or a functional derivative thereof (e.g. a glyceride, methyl or ethyl ester) and an acceptable pharmaceutical vehicle therefor.  The oil extract contains the triglyceride of g -linolenic acid and g -linolenic acid itself and also the methyl ester of linoleic acid.  The preparations are in the form of dosage units and administration may be orally (e.g. tablets, coated tablets, capsules, cachets, powders, granules, syrup or elixir) or parenterally (e.g. sterile liquid solution, suspension or emulsion).
The invention belongs to the technical field of biology, and relates to a polypeptide or a derivative thereof and application thereof in preparation of antitumor drugs. In particular discloses a polypeptide targeting BCL6 or a derivative of the polypeptide and application thereof in preparing medicaments for treating tumors. The amino acid sequence table of the polypeptide is shown as SEQ ID No.1 and SEQ ID No. 2. The polypeptide or the polypeptide derivative can be specifically combined with TRIB so as to block TRIB/BCL 6 interaction and promote the degradation of BCL6 and BCR-ABL proteins, so that the polypeptide or the polypeptide derivative is applied to the preparation of medicaments for treating and preventing breast cancer, lymphoma and lung cancer. The prepared medicine has the advantages of obvious curative effect, less toxic and side effect and safe use in treating tumor diseases.
Methods, systems, and non-transitory computer readable mediums are disclosed for generating health reports. Pet data associated with an entity is received from one or more data sources. Genetic test results data is received from a genetic test results database. The pet data received from the one or more data sources is analyzed with the genetic test results data received from the genetic test results database using an interpretation logic data structure. A result value associated with the pet data and the genetic test results data is determined based on the analysis. One or more result statements associated with the result value are determined and one or more health reports based on the one or more result statements are generated.
OBJECTIVES: The expression of serum free light chain (FLC) is abnormal in various diseases, but its role in lung cancer remains unclear. This study aims to investigate the expression and diagnostic value of serum FLC in lung cancer.
METHODS: A total of 80 lung cancer patients treated at Xiangdong Hospital, Hunan Normal University from January to December 2021 were selected as the lung cancer group. Another 80 healthy individuals undergoing routine physical examinations during the same period were chosen as the control group. General information and serum κFLC and λFLC levels were collected for all subjects. Clinical indicators such as serum carcinoembryonic antigen (CEA), cytokeratin fragment antigen 21-1 (CYFRA21-1) levels, tumor diameter, histological type, TNM stage, and lymph node metastasis status were recorded for lung cancer patients. The expression levels of serum FLC [κFLC, λFLC, and FLC (κ+λ)] were compared between the lung cancer group and the control group. Lung cancer patients were grouped based on gender, age, smoking history, tumor diameter, TNM stage, histological type, and lymph node metastasis to compare differences in serum κFLC and λFLC levels. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value of serum FLC alone and in combination with other indicators in lung cancer.
RESULTS: The expression levels of serum FLC (κ+λ) and κFLC were significantly higher in the lung cancer group than those in the control group (both P<0.001), while there was no significant difference in serum λFLC levels between the 2 groups (P>0.05). There were no significant differences in serum κFLC levels among lung cancer patients with different tumor diameters, histological types, or TNM stages (all P>0.05); however, serum κFLC levels were higher in lung cancer patients with lymph node metastasis than in those without, with statistical significance (P=0.033). There were no significant differences in serum λFLC levels based on tumor diameter or histological type (both P>0.05), but serum λFLC levels were higher in stage III+IV and lymph node metastatic lung cancer patients compared to stage I+II and non-metastatic patients, with statistical significance (P=0.033 and P=0.019, respectively). The area under the curve (AUC) for κFLC and CEA in diagnosing lung cancer showed no significant difference (P=0.333). The combination of κFLC+CYFRA21-1 had the highest diagnostic efficacy (AUC=0.875) and sensitivity (71.3%). The AUC for the combined diagnosis of κFLC+λFLC+CEA+CYFRA21-1 was 0.915 (95% CI 0.860 to 0.953, P<0.001).
CONCLUSIONS: Serum FLC is highly expressed in lung cancer and is associated with its invasion and metastasis. Serum FLC, particularly κFLC, has diagnostic value for lung cancer, and the combined detection of FLC, CEA, and CYFRA21-1 offers the best diagnostic efficacy.
Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
We investigated the potential role of hydrogen sulfide (H2S) as a novel therapy for diabetic peripheral neuropathy in diabetic rats. A single dose of streptozotocin (60 mg/kg) was applied to the rats for the diabetic rat models. Sodium bisulfide (50 μmol/kg/d) was injected intraperitoneally daily for 2 weeks as H2S treatment. Electromyogram, haematoxylin eosin staining, transmission electron microscopy, western blotting and enzyme-linked immunosorbent assay were then performed. H2S treatment did not affect body weights, blood glucose levels or liver function of diabetic rats, while the creatine levels of the H2S-treated diabetic rats decreased compared with the diabetic control rats. H2S treatment for 2 weeks did not affect the sciatic nerve conduction velocity of the diabetic rats. However, H2S treatment relieved neurons loss and cell atrophy of dorsal root ganglion, and axon degeneration of sciatic nerve in diabetic rats. Serum super oxide dismutase (SOD) levels and SOD2 levels in the sciatic nerve of diabetic rats were lower than the non-diabetic rats but were restored after H2S treatment. Serum and sciatic nerve homogenate malondialdehyde and aldose reductase expression were higher in diabetic rats but decreased significantly after H2S treatment. Our study revealed that H2S alleviates neural degeneration in diabetic rats probably by reducing oxidative stress and downregulating aldose reductase expression.
PURPOSE:To obtain an epithelia cell growth promoter useful as a compounding component for an external preparation to shorten a curing period of wound of skin, mucosa, etc., by extracting sevum with a specific solvent. CONSTITUTION:Sevum (e.g. horse sevum) is extracted with water or a hydrophilic solvent (e.g. lower alcohol or dimethylformamide) not dissolving or slightly dissolving sevum. The extraction is carried out by blending sevum with the extracting solvent, uniformly dispersing by shaking, stirring, ultrasonic treatment, etc., allowing to stand or centrifuging the extract and collecting the extracted solvent layer. The collected extract is directly used as an epithelia cell growth promoter or the extracting solvent is removed by distillation under reduced pressure and freeze drying or, spray drying, etc., and the residue is used as epithelia cell growth promoter. The promoter shows effects on wounds such as cut, bruise, rupture, burn, congelation, bedscore and sunburn dermatitis. The epithelia cell growth promoter is useful as a compounding component for various kinds of cosmetics useful for beauty of skin, etc., such as make-up cream, lipstick, hair dressing agent, etc.
Renal anisotropy is a complex property of the kidney and often poses a challenge in obtaining consistent measurements when using shear wave elastography to detect chronic kidney disease. To circumvent the challenge posed by renal anisotropy in clinical settings, a dimensionless biomarker termed the 'anisotropic ratio' was introduced to establish a correlation between changes in degree of renal anisotropy and progression of chronic kidney disease through an in silico perspective. To achieve this, an efficient model reduction approach was developed to model the anisotropic property of kidneys. Good agreement between the numerical and experimental data were obtained, as percentage errors of less than 5.5% were reported when compared against experimental phantom measurement from the literature. To demonstrate the applicability of the model to clinical measurements, the anisotropic ratio of sheep kidneys was quantified, with both numerical and derived experimental results reporting a value of .667. Analysis of the anisotropic ratio with progression of chronic kidney disease demonstrated that patients with normal kidneys would have a lower anisotropic ratio of .872 as opposed to patients suffering from renal impairment, in which the anisotropic ratio may increase to .904, as determined from this study. The findings demonstrate the potential of the anisotropic ratio in improving the detection of chronic kidney disease using shear wave elastography.
The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.